DNAM-1 (DNAX Accessory Molecule-1) also known as CD226 (Cluster of Differentiation 226) or PTA1, is a ~65 kDa glycoprotein expressed on the surface of natural killer cells, platelets, monocytes and a subset of T cells. DNAX accessory molecule-1 (DNAM-1), plays an important role in the NK cell-mediated recognition and killing of Multiple myeloma cells. Tumor cells can express DNAX-1 ligands. Recently, scientists have identified the poliovirus receptor (PVR) CD155 and its family member CD112 (PVRrelated family 2 [PRR-2], also called as nectin-2), as the ligands for human DNAM-1. Although the human DNAM-1 ligands CD112 and CD155 are broadly distributed on epithelial and endothelial cells in many tissues, they are overexpressed on certain human tumors, including colorectal carcinomas, myeloid leukemias,14 and neuroblastomas, suggesting that the expression of DNAM-1 ligands is inducible by "stress" such as transformation and infection.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE